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Abstract
Background: Myocardial infarction (MI) due to coronary artery disease remains one of the leading causes of premature
death. Replacement of infarcted heart tissue with regenerating myocardium from endogenous progenitor pools or
exogenously introduced stem cells remains a therapeutic ideal. Their impracticality mainly lies in their low efficiency in
cardiogenic differentiation (CD). Our recent studies with an acute MI animal model have already demonstrated the
therapeutic effect of the MeOH extract of Geum japonicum (EGJ), providing clear evidence of myocardial regeneration.
Methods and Findings: The present study further isolated the active component contained in EGJ using bioassay-guided
isolation and investigated its efficacy in the treatment of infarcted heart in animal MI models. We demonstrated that
substantial repair of infarcted heart in animal MI models by EGJ can be mimicked by the isolated candidate compound
(cardiogenin) in MI animal models. Clear evidence of newly regenerated endogenous mesenchymal stem cells (MSCs)
derived cardiomyocytes was observed throughout the infarct zone, accompanied by significantly improved functional
performance of the heart. Transplantation of MSCs pretreated with EGJ or cardiogenin into a MI animal model also resulted
in substantial regeneration of functional myocardium, implying that the activated MSCs carry all the necessary blueprints for
myocardial regeneration. Signaling pathways specific to cell survival, CD identified in embryonic heart induction and
angiogenesis were activated in both cardiogenin-treated MSCs and cardiogenin-induced regenerating myocardium.
Conclusions: This study has demonstrated the therapeutic effects of cardiogenin in infarcted heart repair, and identified the
associated signalling pathways for effective cardiogenic differentiation of MSCs, cell survival and angiogenesis. These
findings should enable new treatment strategies for MI to be developed immediately.
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Introduction
Despite significant therapeutic advances, replacement of
infarcted heart tissue with regenerating myocardium remains a
therapeutic ideal as it is almost impossible for adult cardiomyo-
cytes to repopulate [1–8]. The recent observation that a
population of myocytes within the myocardium can replicate after
infarction [9] has triggered an intense search for progenitor cells
that can replace damaged myocardium. Transplantation of
cardiomyocytes or myoblasts have both failed to reconstitute
functional myocardium [3–5]. Transplantation of adult bone
marrow (BM) derived MSCs following MI has been shown to
produce some cardiomyogenesis, but majority of the newly
regenerated cardiomyocytes appeared to be scattered along the
less-ischemic border zone [7,8]. This signifies that the transplanted
MSCs had insufficient CD to form the integrated units necessary
for regenerating functional myocardium. Considerable efforts have
therefore been focused on searching for new ways to enhance
cardiogenic differentiation efficiency (CDE) from a variety of
potential progenitor cells, including embryonic stem cells,
hemotopoietic stem cells and MSCs, since this is essential for
myocardial regeneration as a viable and practical therapy for MI.
However, the molecular mechanisms by which candidate
progenitors can be stimulated to differentiate into cardiomyocytes
remain largely unknown. An alternative solution is to search for
molecules that can devise mechanisms which increase CDE in
endogenous candidate progenitors.
In search of molecules promoting CDE, it is surprising to learn
that the Miao, an ethnic group in China’s Guizhou province, live
significantly longer than other ethnic groups inhabiting the same
region. A possible explanation for their longevity is that for
centuries they have used their own kind of traditional medicine,
which differs considerably from traditional Chinese medicine. We
therefore screened the herbs frequently used in Miao medicine for
treating common diseases that might possibly contribute to their
longevity. One potential candidate was Geum japonicum, a herb used
PLoS ONE | www.plosone.org 1 February 2009 | Volume 4 | Issue 2 | e4461as a diuretic and an astringent [10] in Chinese medicine, but is
also one of the commonly used herbs in many Miao medicine
formulas. Our recent studies with an acute MI animal model have
already demonstrated the therapeutic effect of EGJ, providing
clear evidence of myocardial regeneration [11]. These findings
have prompted the present investigation for the identification and
isolation of the active components of EGJ, demonstration of its
therapeutic effect for MI and elucidation of possible underlying
signaling mechanisms.
Methods
Ethics Statement
All animal experiment protocols conformed to the Guide for the
Care and Use of Laboratory Animals published by the U.S.
National Institutes of Health, and approved by the Animal
Experimental Ethical Committee of The Chinese University of
Hong Kong.
Bio-assay Guided Isolation of Cardiogenin from Geum
Japonicum
Geum japonicum collected from the Guizhou Province of China in
August was dried, cut and percolated with 70% MeOH at room
temperature for 6 days. The EGJ was produced as previously
described [11]. The cardiogenic compounds was isolated from
EGJ using a bio-assay guided strategy. As shown in the flow chart
(Fig. 1), the isolation of the cardiogenic compound (cardiogenin)
was attained by the following procedures: (i) the EGJ powder
showing significant cardiogenic activity in MI animal model was
prepared; (ii) the EGJ was suspended and partitioned with H2O
and successively partitioned with CHCl3, EtOAc and n-BuOH
respectively, whereby all 3 fractions were evaporated under
reduced pressure (38uC) and yielded 3 different fractions; (iii) the
cardiogenic-promoting effect of the three fractions was tested with
MI animal models and it was found that the n-butanol fraction
significantly enhanced myocardial regeneration in infarcted hearts;
(iv) the n-butanol fraction was applied on a column of Diaion
HP20 equilibrated with 10% MeOH and eluted with increasing
concentration of MeOH in H2O, resolving 7 fractions; (v) activity
testing in stimulating myocardial regeneration in a MI animal
model demonstrated that fraction 6 was active in promoting
myocardial regeneration in vivo while none of the other fractions
together produced a significant cardiogenic effect, indicating that
fraction 6 contained the active component responsible for the
observed cardiogenic-enhancing effect of EGJ; (vi) further
separation of fraction 6 by Silica Gel column chromatography
isolated a major compound (C36H58O11) with proven in vitro and in
vivo cardiogenic activity, herein termed cardiogenin. The chemical
structure of cardiogenin was elucidated by NMR and MS analyses
and compared with databases (ChemFinder, ChemACX Pro and
ChemACX-SC Pro) and previous publications.
MI Animal Model, Treatment Protocol and Assessment
MI was induced in male Sprague-Dawley rats (300,350 g) by
permanent ligation of the left anterior descending (LAD) coronary
artery as previously described [11]. Each rat was anesthetized with
intraperitoneal pentobarbital (50 mg/kg), intubated, and mechan-
ically ventilated with room air using a Harvard ventilator (model
683). EGJ (300 mg/kg) or cardiogenin (0.3 mg/kg) dissolved in
5% DMSO (0.5 ml) was orally administrated to MI rats 1 day
(acute) or 2 weeks (old) post ligation, daily for 2 weeks with
equivalent amount of 5% DMSO to the sham-treated rats. For
sham-operated rats (n=8), thoracotomy was performed without
LAD ligation.
Animals were sacrificed after final echocardiography mea-
surements were recorded on day 7 and 14 post operations. The
hearts of the sacrificed rats were removed and washed with PBS.
All the specimens harvested were either sectioned for histological
and immunohistochemical analyses or used for Western blot and
DNA microarray studies. For histological examination, the left
ventricles of the experimental rats sacrificed on day 7 and 14
were removed and cut from apex-to-base in 3 transverse slices
and embedded in paraffin. The infarct size and vascular density
in infarct zones were measured accordingly. Infarct size was
expressed as a percentage of the total left ventricular area. To
quantify the average number of capillaries in central infarct
zones, 16 sections from within the central infarct zone of each
heart were analysed, in which capillaries were counted and
averaged in 6 randomly selected high power view fields (HPF,
406) on each section. Blinded capillary counts were performed
on 6–8 hearts per group by two investigators. The results were
expressed as mean6SD capillaries per HPF. The detailed
procedures for identification of the regenerating cardiomyocytes
and myocardium; determination of the total volume of
regenerating myocardium for hearts in each group; and related
immunohistochemical analyses conducted in this study have
been described in our previous report [11].
Construction of Myosin Light Chain 2v-Promoted EGFP
(MLC-GFP) Plasmid and its Transfection to MSCs
A recombinant expression vector was constructed by cloning a
2.7 kb HindIII–EcoRI fragment of the rat MLC-2v promoter
region [5] into the HindIII–EcoRI site of pEGFP-1 plasmid
(Clontech, Palo Alto, CA) to form a MLC-GFP plasmid, allowing
GFP expression to be controlled by the MLC-2v promoter. To
validate the construction, the pEGFP-1 plasmid and the
constructed MLC-GFP plasmid with rat MLC-2v promoter were
transfected to MSCs respectively. The non-transfected MSCs,
transfected MSCs with a pEGFP-1 plasmid, and MSCs with a
MLC-GFP plasmid were then treated with cardiogenin respec-
tively. The results derived from this validation experiment
demonstrated that (i) although cardiogenin-treated non-transfected
MSCs showed an elongated phenotype compared to non-
phenotypic changes in sham-treated cells, no GFP expression
was observed, indicating that no endogenous GFP was stimulated;
(ii) although cardiogenin-treated and sham-treated pEGFP-1
transfected MSCs underwent different phenotypic changes, both
the cardiogenin-treated and sham-treated cells expressed GFP; (iii)
a much higher percentage of cardiogenin-treated MLC-GFP
plasmid transfected MSCs expressed GFP after 7 days treatment
compared to a very low percentage of GFP expression observed in
the sham-treated cells. The latter is probably due to unspecific
leakage of the plasmid construction. This plasmid also contains the
neomycin-resistance gene to enable selection of permanently
transfected clones. The MLC-GFP plasmid was transfected into
MSCs by liposomal transfection. After 24 h when cells are ,90%
confluent, a mixture containing 2.5 mg of plasmid DNA and 5 ml
of Lipofectamine
TM 2000 transfection reagent (Invitrogen) in
OPTI-MEM
RI (Invitrogen) were added to each 35 mm culture
dish. After selection with 600 mg/ml of G418 for 4 weeks, stably
transfected colonies were cloned and pooled. EGFP fluorescence
was observed under a fluorescence microscope (Olympus
TMD300, Tokyo, Japan).
Assessment of EGJ/Cardiogenin-induced CDE of MSC
The tibias/femur bones of rats were removed and the BM was
flushed out of the bones with alpha IMDM culture medium. The
BM was mixed well and centrifuged at 1,500 rpm for 5 min. The
Repair of Heart Infarction
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suspension was carefully put on 4 ml Ficoll solution to minimize
disturbance and centrifuged at 200 rpm for 30 min. The second
layer was transferred into a tube and washed twice with PBS to
remove Ficoll (1,200 rpm for 5 min.). The cell pellet was
resuspended in IMDM culture medium containing 10% heat
inactivated FBS (GIBCO) and 1% penicillin/streptomycin antibi-
otic mixture and used for in vitro and in vivo studies. Non-adherent
cells were discarded after 24 h culturing. The adherent cells were
cultured by changing medium every 3 days and the cells became
nearly confluent after 14 days culture. The MSCs were cultured
with EGJ (60 mg/ml IMDM culture medium) or cardiogenin
(10 mg/ml) for 3–4 and 6–7 days to sequentially activate
cardiogenic specific genes’ expression and morphology transition.
The time-dependent expression of MEF2, GATA4,myosin heavy
chain (MHC) and actin was assessed by immunecytochemistry at
different time points. Briefly, cultured cells were fixed with 4%
paraformaldehyde in PBS for 15 min and permeabilized with
0.5% Triton X-100 for 15 min. Dilution of antibodies was as
follows: mouse monoclonal antibodies specific to MEF2 (1:500),
GATA4 (1:300), MHC (1:600) and actin (1:500) (all from Santa
Cruz). Secondary antibodies were goat anti-mouse IgG antibodies-
conjugated with peroxides or Fluorophore (DyeMer
TM 488/630
and 496/520) (Molecular Probe). The nuclei were stained with
DAPI. For cell transplantation, both the cardiogenin-pretreated
MSCs and the sham-treated MSCs were labeled with CM-DiI on
day 3 of the cultures [4] prior to transplantation. CD associated
morphological transition of MSCs was also examined by phase-
contrast microscopic and immunocytochemical studies.
Transplantation of Cardiogenin-pretreated MSCs and
Assessment of Its Effect on Myocardial Regeneration
MI was induced by permanent ligation of LAD coronary artery
of 24 rats as previously described [11]. For cell transplantation, the
5610
6 DiI-labeled cardiogenin-pretreated MSCs suspended
(0.1 ml) in saline were injected into the blood stream of the 12
newly-induced MI rats in the test group. In parallel, the sham-
treated group (n=12) was injected with an equivalent amount of
sham-pretreated DiI-labeled MSCs suspended in saline at the
same injection site. Six experimental rats of both groups were
sacrificed on day 7 and 14 respectively. The hearts of the sacrificed
rats were removed, washed with PBS and photographed
respectively. All specimens harvested were paraffin embedded
and sectioned for tracing the signals of DiI florescence and
examination of infarct size and myocardial regeneration. Coloca-
lization of DiI label and cardiac-specific marker expression was
examined and used to indicate CD of transplanted cells. The
determinations of infarct size and capillary density in different
groups of MI rats were carried out as described in our previous
report [11].
The MSCs were cultured with cardiogenin (10 mg/ml) for 3 and
6 days to sequentially activate cardiogenic specific gene expres-
sions. Prior to transplantation, both the cardiogenin-pretreated
and the sham-pretreated control MSCs were labeled with CM-DiI
on day 3 of the cultures. For cell transplantation, 5610
6 DiI-
labeled cardiogenin- or sham-pretreated MSCs suspended (0.1 ml)
in saline were injected into the blood stream through the tail vein
immediately after LAD ligation in test and sham-treated groups
respectively.
Echocardiography Assessment of Heart Function
Echocardiography was recorded in all experimental subjects
before and after EGJ/cardiogenin treatment, under controlled
anesthesia, using a S10-MHz phased-array transducer and GE
VingMed Vivid 7 system. M-mode tracing and 2D echocardiog-
raphy images were recorded from the parasternal long- and short-
axis views. Short-axis view was at the papillary muscles level. Left
ventricular (LV) end-systolic and end-diastolic dimensions, as well
as systolic and diastolic wall thickness were measured from the M-
mode tracings by using the leading-edge convention of the
American Society of Echocardiography. For each M-mode
measurement, at least three consecutive cardiac cycles were
sampled. LV end-diastolic (LVEDA) and end-systolic (LVESA)
areas were planimetered from the parasternal long axis. LV end-
diastolic and end-systolic volumes (LVEDV and LVESV) were
calculated by the M-mode method. LV ejection fraction (LVEF)
and fractional shortening (LVFS) were derived from LV cross-
sectional area in 2D short-axis view: LVEF=[(LVEDV2L-
VESV)/LVEDV]6100% and LVFS=[(LVEDA2LVESA)/
LVEDA]6100%. Standard formulae were used for echocardio-
graphic calculations [2]. All data were analyzed offline with
software installed in the ultrasound system. All measured and
calculated indexes were presented as the average of three to five
consecutive measurements.
Signaling Pathway-specific Gene Expression Profiling and
Genome Array Analyses
To determine the cellular origin of the regenerated myocardium
and possible driving force involved in the processes of myocardial
regeneration in infarcted hearts in vivo and CD of MSCs in vitro,
signaling pathway-specific gene expression profiling analyses with
Oligo GEarrayH Rat Transduction Pathway Finder
TM Microarray
(SupperArray Bioscience Corporation) and GeneChip System Rat
Genome 230 2.0 microarray (Affymetrix Inc. Santa Clara, CA)
were performed with both cell and tissue samples. The cell samples
were obtained from cultured MSCs treated with cardiogenin
(5 mg/ml) and from MSCs treated with the equivalent amount of
5% DMSO at different durations of 12 h, 3, 7 and 14 days. The
tissue samples were harvested from infarcted zones of EGJ-treated
and sham-treated hearts, 3 days post treatment. All samples were
sent to the Genome Center at the University of Hong Kong for
analysis.
Total RNA was extracted from above prepared cell samples and
infarcted heart tissue respectively. Each sample was homogenized
using a Brinkmann PT 10/35 tissue homogenizer (Brinkmann
Instruments, Inc, Westbury, NY) at medium speed for 30 to
60 sec. RNA was extracted using Trizol (Invitrogen) according to
manufacturer’s instructions. The total RNA concentration of each
sample was determined by absorbance at 260 nm. All RNA
preparations from both cell and tissue samples were treated with
DNAase. The cRNA synthesis, labeling and amplification were
performed according to the user manual of the TrueLabeling-
Figure 1. Bioassay-guided isolation of cardiogenin and its chemical structure. a, Diagram of bio-assay guided isolation of cardiogenin from
Geum japonicum. ,10% EGJ was extracted from the dried whole plant. The n-butanol fraction (GJ-B) from EGJ (18%) showed cardiogenic activity.
Fraction 6 (GJ-B-6) was isolated from GJ-B by Diaion HP20 resin column chromatography and was shown to enhance myocardial regeneration. A
cardiogenic fraction (GJ-B-6-2) was further isolated from GJ-B-6 using Silica gel column chromatography; and finally one cardiogenic compound
(cardiogenin) was isolated from GJ-B-6-2 using RP-HPLC (C18). The recovery rate of the cardiogenin from GJ-B-6 or the dried whole plant is ,0.5% or
0.8%´. b, Chemical structure of the isolated active component (chemically named Niga-ichigoside F1).
doi:10.1371/journal.pone.0004461.g001
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TM Linear RNA amplification kit. The synthesized cRNA
were labeled with biotin (Roche). Prehybridization was performed
in a hybridization oven at 60uC for 2 h; the biotin-labeled cRNA
was then added into the prewarmed hybridization solution and
hybridization continued at 60uC overnight. Chemiluminescent
detection was then performed to capture the signal according to
the manufacturer’s instructions. Hybridization signals were
detected by film exposure and analyzed by peptidylprolyl
isomerase in the blots as an internal control for normalization.
Inhibition of BMP-4 to Reduce CDE of MSC in vitro and in
vivo
MSCs were cultured with cardiogenin (10 mg/ml) in the
presence of a specific inhibitor of BMPs, noggin (10 ng/ml), for
4 days. The noggin-mediated suppression of cardiogenin-induced
early- and further-CD was assessed by immunocytochemistry and
Western blot analysis against MEF2 (on day 3 of culturing) and
MHC (on day 6 of culturing), respectively. To confirm BMPs were
involved in myocardial regeneration in vivo, on day 3 of the
cultures, the cardiogenin-pretreated MSCs in the presence of
noggin were labeled with CM-DiI in culture prior to transplan-
tation. The labeled MSCs were injected into the blood stream of
experimental rats with a newly made MI. Two and 3 weeks post
infarction and MSC transplantation, whether the noggin mediated
suppression of CD in vitro would affect myocardial regeneration in
vivo was assessed.
Statistics
All data were presented as mean6SD. Statistical significance for
comparison between two measurements was determined by
unpaired Two-tailed Student t-tests. Values of p,0.05 are
considered to be significant.
Results
Isolation of Cardiogenin and Repair of Acute MI
To identify and isolate the cardiogenic compound contained in
EGJ, EGJ was attained by bio-assay guided fractionation (Fig. 1a).
The chemical structure of the isolated cardiogenic-compound was
determined by NMR and MS, and subsequently cross-referenced
to databases (Fig. 1b). The therapeutic effect of the isolated
compound, cardiogenin (chemically named Niga-ichigoside F1),
was then compared with that of EGJ in the acute rat MI model to
mimic acute MI in human patients. Although the area (4–6 mm in
diameter) distal to the ligation site appeared pure white and thin
due to ischemic necrosis in sham-treated hearts 14 days post
infarction (Fig. 2a), the corresponding areas in both EGJ2 (Fig. 2b)
and cardiogenin-treated hearts (Fig. 2c) appeared red and the
thickness of the ventricle and septal walls were well maintained.
These observations are suggestive of possible infarction repair and
myocardial regeneration. Histological examination revealed that
the average infarct size, calculated as a percentage of the infarct
volume of the total LV volume, in both EGJ and cardiogenin-
treated hearts (n=8 for each group, 1866.9% and 2067.3%,
respectively) was ,1/2–1/3 times smaller than that of sham-
treated hearts (n=8, 3667.3%) (p,0.001) on day 14 post
infarction. The fibrous replacement is characteristic throughout
the infarct region of sham-treated hearts (Fig. 2a). In sharp
contrast, the infarct zones in both EGJ2 (Fig. 2b) and
cardiogenin-treated hearts (Fig. 2c) were mostly covered by cells
of typical cardiomyocyte-like morphology. However their sizes
were ,1/3–1/4 smaller than that of non-infarcted normal
myocytes on the infarct border and distal regions, implying that
these cardiomyocyte-like cells were newly regenerated. The
cardiomyocyte-like cells clustered and organized into myocardi-
al-like tissue throughout the infarct zone which were positively
stained by antibodies specific to proliferation marker Ki67 and
MHC (Fig. 2b:iv, c:iv) confirming that they are newly regenerated
cardiomyocytes. These observations imply that both EGJ and
cardiogenin have the capacity to enhance CDE, thereby
accelerating MI repair.
To demonstrate that the significant cardiac regeneration in the
cardiogenin-treated MI hearts was accompanied by progressively
improved functional performance, echocardiography was per-
formed at different time points before and after cardiogenin or
sham (n=8 for each group) treatment. It was found that the wall
motion of the LV anterior wall (LVAW) in cardiogenin-treated
hearts was gradually restored, while the LVAW in sham-treated
hearts were thinned and akinetic, which developed into paradox-
ical motion 1–4 weeks post infarction (Fig. 3). Progressive
restoration of the systolic/diastolic volume in cardiogenin-treated
hearts was also evident (Fig. 3a). The time-dependent functional
improvement in terms of LVEF and LVFS in the cardiogenin-
treated group was significant (Fig. 3b).
Cardiogenin Induced Substantial Repair of Old Infarcted
Heart
To further demonstrate the therapeutic effect of cardiogenin on
old infarcted hearts to mimic the commonest situation in patients,
MI animals (n=10) received oral administration of cardiogenin
dissolved in 5%DMSO (0.3 mg/kg) or equivalent amount of 5%
DMSO 2 weeks post LAD ligation for 2 weeks. Measurements
taken before treatment and at 1, 2 and 4 weeks after cardiogenin
or sham treatment in old MI rats (Table 1) showed that heart
function was significantly improved with progressively restored
LVAW motion (originally motionless at 2 weeks post ligation) and
systolic/diastolic volume, similar to cardiogenin-treated acute MI
hearts. Consistent with sham treatment in the acute MI model, LV
systolic/diastolic volumes progressively increased in sham-treated
old MI rats. Furthermore, at 4 weeks post infarction, systolic
performance worsened with anterior wall akinesis which devel-
oped into paradoxical motion (Table 1). The time-dependent
functional improvement in acute MI cardiogenin-treated hearts
was also apparent in the old MI cardiogenin-treated hearts. The
results obtained from acute and old MI experiments suggest that
cardiogenin is an active component from EGJ responsible for the
observed myocardial regeneration.
Endogenous MSCs are Involved in Acute Myocardial
Regeneration
To determine the particular cell type contributing to EGJ/
cardiogenin-induced myocardial regeneration, genome array
analysis was conducted to examine the expression of cell markers.
Results showed MSC-specific markers including CD29, BST-1,
SDF-1 and SDF-4, were detected in EGJ-treated tissues 3 days
post infarction, indicating their MSC origin. We thus hypothesized
that EGJ/cardiogenin could induce CD in MSCs at an efficient
rate sufficient for myocardial regeneration. Hence the effect of
EGJ/cardiogenin in inducing CD of MSCs in vitro was studied.
MSCs cultured in medium containing EGJ (60 mg/ml) or
cardiogenin (10 mg/ml) were stained positive for antibodies
specific to two of the earliest cardiogenic lineage markers, MEF2
(.90%) and GATA4 (.70%), respectively (Fig. 4a and b),
signifying their early commitment to CD. Phase-contrast micros-
copy demonstrated that treated MSCs differentiated into elongat-
ed cells, some of which showed a recognizable striated appearance,
differing from the irregularly shaped undifferentiated MSCs in the
Repair of Heart Infarction
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MSCs, MLC-GFP-transfected MSCs were treated with EGJ
(60 mg/ml) or cardiogenin (10 mg/ml) for 3 and 6 days. It was
found that .70% and 50% of the MSCs became rod-shaped with
green fluorescence, respectively (Fig. 4c and d), which can only be
observed with the expression of cardiac-specific MLC. This
phenotype verifies the differentiation of MSCs into cardiac
progenitors. In sharp contrast, ,6% of the sham-treated cells
displayed green fluorescence on day 6. These results suggest that
both EGJ and cardiogenin can significantly increase CDE in
MSCs in vitro, which we hypothesized could be sufficient for
myocardial regeneration in vivo.
Cardiogenin-activated MSCs Repaired MI
To test whether increased CDE in progenitor cells alone could
lead to significant myocardial regeneration for repair of infarcted
hearts in vivo, DiI-labeled MSCs were pretreated with cardiogenin
for 3 days and washed thoroughly to remove residual cardiogenin
prior to injection of the cells into the blood stream of newly-induced
MI rats. One week post infarction and cell transplantation,
Figure 2. Significant repair of infarcted myocardia in acute MI rat model by EGJ/cardiogenin treatment. a, Sham-treated heart. Ligation
site (upper circle) and a pale distal region (lower circle) (i). Heart cross-section showing the infarcted area (ii). HE stained section (iii). Ki67 (black
nuclei) immuno-eosin-counter-stained section (iv), showing inflammatory cell infiltration and fibrous tissue replacement in the whole infarct zone
(INF). EGJ2 (b) and cardiogenin-treated (c) hearts with the ligation sites circled (b:i, c:i) and a corresponding heart cross-sections showing the
infarcted area (b:ii, c:ii); HE stained sections (b:iii, c:iii). Ki67 immuno-eosin-counter-stained section (b:iv). Double Ki67 and MHC (brown) immuno-
counter-stained sections (c:iv). Large number of regenerating myocytes (RM), distributed throughout the infarcted areas in treated hearts (b:iv, c:iv).
However they are ,1/3–1/4 times smaller than non-infarcted normal myocytes (NM). The regenerating cells formed bundles characteristic of typical
myocardial morphology with Ki67 positively stained nuclei and MHC positively stained cytoplasm.
doi:10.1371/journal.pone.0004461.g002
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showed numerous DiI and MEF2 colocalized cells in MI hearts
transplanted with cardiogenin-activated MSCs, confirming their
donor cell origin and in vivo cardiomyogenic differentiation (Fig. 4e).
Furthermore, these cells aligned in similar orientation with viable
non-infarcted cardiomyocytes and distributed throughout the
infarct zones. Additionally, significantly more MEF2-positive cells
were detected at 14 days than at 7 days post-treatment (Fig. 4e). By
contrast, much less DiI and MEF2 colocalized cells were observed
in the hearts transplanted with sham-pretreated MSCs (Fig. 4e),
possibly due to the low CDE in the sham-treated MSCs. Capillary
density in the infarct area of hearts transplanted with cardiogenin-
activated MSCs 7 days post transplantation was on average 1363
per HPF (Fig. 4e), whereas only 562 vessels per HPF were in the
infarct zone of hearts transplanted with sham-pretreated MSCs.
The highly organized regenerating myocardium-like tissues in the
hearts transplanted with cardiogenin-activated MSCs occupied on
average 6368.0% of the total infarct volume 7 days post treatment
as compared to ,863.6% in hearts receiving sham-treated MSCs.
Collectively, these results suggest that the ability of EGJ/
cardiogenin to repair infarcted heart could be due to their ability
to increase CDE of endogenous MSCs.
Signaling Pathways are Possibly Involved in Cardiogenin-
mediated Myocardial Regeneration
Activation of signaling pathways using Oligo GEarrayH Rat
Transduction Pathway Finder
TM Microarray was used to
determine the possible signaling pathways involved in mediating
the therapeutic effect of EGJ/cardiogenin on CD and MI repair.
The results showed that similar signaling pathways were activated
in both cardiogenin-treated MSCs in vitro and EGJ-treated hearts
in vivo 3 days post treatment (Fig. 5a). We then further examined
time-dependent activation of these signaling pathways during
cardiogenin-induced CD in MSCs using the same microarray. It
was demonstrated that cardiogenin treatment of MSCs in vitro
induced activation of several signaling pathways, including Wnt,
TGF-b, JAK-STAT and NFkB pathways (Fig. 5b:i–v). Most of
these signaling pathways were activated/upregulated 1 h after
treatment, and kept increasing at 12 h, peaked on day 3, and
declined on day 7 and 14 (Fig. 5b:iii). The time-dependent
expression profiles of these pathway-specific key genes were
further confirmed by RT-PCR analysis (Fig. 5b:iv and v). The
activation of these four signaling pathways, which have been
studied extensively and implicated in early heart induction during
embryonic development [13], is consistent with their role in
Figure 3. Echocardiography demonstration of improved heart function induced by cardiogenin treatment. a, Representative M-mode
and end systolic/diastolic short-axis cross sectional images of the LV at the level of the papillary muscle of cardiogenin-treated (a:i) and of sham-
treated (a:ii) MI hearts. M-mode measurements of a short-axis view showed motion of heart structure throughout several cycles (a:M); systolic short-
axis view (a:S); and diastolic short-axis view (a:D). Images taken one day post ligation (a:0); 1 (a:1) and 2 weeks (a:2) treatment with cardiogenin or
sham. One day ligation (a:0) resulted in anterior akinesis (yellow arrows) and marked LV dilation (blue arrowheads) in both groups of animals. One
(a:i-1) and 2 (a:i-2) week cardiogenin treatment significantly and increasingly improved the LVAW motion (red arrow) and reduced systolic/diastolic
(blue arrowheads) volumes. Sham-treated hearts showed progressive increases in systolic/diastolic volumes (a:ii-S,D, blue arrowheads). Systolic
performance progressively worsened with anterior akinesis developing into paradoxical motion (a:ii-M, green arrows and circles). The LVAW
thickness in cardiogenin-treated heart (a:i-S,D), (a:i-D, the space between the green and blue arrowheads) gradually increased, with non-visible
changes of LV posterior wall thickness (the space between blue and pink arrowheads). Both the anterior and posterior LV wall thickness in sham-
treated heart (a:ii-S,D) became increasingly thin. b, Echocardiography with LVEF (b:i) and LVFS (b:ii) demonstrating improved heart function with
time by cardiogenin treatment (Car-treated). Sham-treated (Sham-treated) vs cardiogenin-treated hearts before ligation (baseline), 0–4 weeks
after cardiogenin/sham treatment. Both graphs show regain of cardiac function in cardiogenin-treated but not sham-treated hearts (n=8 for each
group), in which p=0.005 for week 1, p=0.001 for weeks 2 and 4. Sham-Op refers to open-chest operation without LAD ligation.
doi:10.1371/journal.pone.0004461.g003
Table 1. Echocardiography evaluation of LV function in old MI rats.
Evaluations
Two weeks post MI prior to
treatment Post treatment Post/prior%
Car Sham Car Sham Car Sham
LVEDD (nm) 7.362.9* 8.062.1* 28.7* +1.3*
8.062.2 7.962.3 6.862.6** 8.762.6** 215.0** +10.1**
6.462.5*** 9.162.8*** 220.0*** +15.2***
LVESD (nm) 4.862.5* 5.662.5* 217.0* 21.8*
5.862.1 5.762.0 4.362.1** 6.362.3** 225.8** +10.5**
3.862.2*** 7.263.0*** 234.4*** +26.3***
48.866.1* 41.865.3* +21.7* 21.9*
LVEF 40.164.8 42.665.1 60.166.6** 40.164.9** +49.8** 25.9**
65.465.5*** 37.365.0*** +63.0*** 212.4***
32.264.3* 27.864.1* +15.4* 25.1*
LVFS 27.965.2 29.364.8 35.864.8** 27.664.8** +28.3** 25.8**
39.165.5*** 25.663.9*** +40.1*** 212.6***
LVESD: left ventricular end systolic diameter; LVEDD: left ventricular end diastolic diameter; LVEF: ejection fraction; LVFS: fraction shortening, *1; **2; ***4 weeks post
treatment.
doi:10.1371/journal.pone.0004461.t001
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PLoS ONE | www.plosone.org 8 February 2009 | Volume 4 | Issue 2 | e4461Figure 4. EGJ/cardiogenin-enhanced CDE of MSCs in vitro and in vivo.a , EGJ-treated and b, cardiogenin-treated MSCs double-stained with
DAPI (blue nuclei) and specific early markers of CD, MEF2 (E-MEF2, Car-MEF2) and GATA4 (E-GATA4, Car-GATA4); with corresponding sham-
treated MSCs stained positive for DAPI but negative for CD markers (S-MEF2, S-GATA4). Note the presence of a DAPI-positive but MEF2-negative
nucleus among other MEF2-positive nuclei in EGJ-treated MSCs (E-MEF2, white arrow) is possibly due to a proportion of MSCs not committed to
cardiac differentiation, which may also serve as a negative control. Three days post treatment, cells were immunocytochemically stained against
MEF2 and GATA4 individually, and then the nuclei were stained blue with DAPI. Low magnification phase-contrast images and green fluorescent
micrographs of EGJ-treated (c) and cardiogenin-treated (d) MSCs. Six days post treatment, both EGJ- and cardiogenin-treated MSCs were elongated
with characteristic striated appearance (c:E-P, d:Car-P) and GFP-positive (c:E-GFP, d:Car-GFP) in contrast to the irregularly shaped MSCs and
absence of green fluorescence in sham-treated cells (c:S-P, d:S-P, c:S-GFP, d:S-GFP). e, MEF2-immunostained and DiI-labeled heart tissues
demonstrating in vivo CD of cadiogenin-activated MSCs at 7 days (i) and 14 days (ii) after transplantation to MI hearts. Sham-treated MSCs 14 days
after transplantation (iii). Numerous DiI (orange) and MEF2 (red) colocalized cells bearing cardiomyocyte phenotype (blue circles) aligning in similar
orientation with pre-existing cardiomyocytes were observed with many capillaries (i–ii, yellow circles) found throughout the infarct zone of
cardiogenin-activated MSC-transplanted MI hearts. In sham-treated MSC transplanted MI hearts, only DiI-positive cells without MEF2 colocalization
(iii, green circles) were observed scattering along the infarct zone.
doi:10.1371/journal.pone.0004461.g004
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PLoS ONE | www.plosone.org 10 February 2009 | Volume 4 | Issue 2 | e4461promoting CD in MSCs and myocardial regeneration in infarcted
hearts treated with EGJ/cardiogenin.
BMP-4 of the TGF-b pathway was found in the present study to
be one of the earliest genes maximally upregulated in both EGJ-
induced myocardial regeneration and cardiogenin-induced CD in
MSCs. In a previous publication, BMPs induced cardiac
differentiation of P19CL6 in vitro, in which the cardiac differen-
tiation was blocked by noggin, a specific inhibitor of BMPs [12].
Therefore, to verify the involvement of BMP-4 in CD of MSCs
and MI repair, noggin (R and D Systems) was used to suppress
cardiogenin-induced CD of MSCs. As shown in Figure 6, .90%
of MSCs treated with cardiogenin for 3–4 days were found to be
immunoreactive with MEF2 antibody (Fig. 6b), while ,50% of
the cardiogenin-treated MSCs in the presence of noggin (10 ng/
ml) were MEF2-positive (Fig. 6c). These results indicated
significant reduction in cardiogenin-enhanced CDE of MSCs,
which was further confirmed by Western blot analysis. Where, the
expression of MEF2 in cardiogenin-treated MSCs with noggin was
indeed 2.3 folds less than that in the absence of noggin (Fig. 6g),
confirming the inhibition of BMP signaling by noggin. Similarly,
only ,55% of the cardiogenin-activated MSCs in the presence of
noggin was positively stained with antibody specific to MHC,
while ,95% of the MHC-positive cells was observed in the
cardiogenin-treated MSCs without noggin. These results demon-
strated that inhibition of BMP-4 by noggin leads to reduced
cardiogenin-enhanced CDE of MSCs in vitro.
To test whether cardiogenin-induced cardiomyogenic differen-
tiation in vivo could be suppressed by inhibition of BMP signaling,
we further transplanted the cardiogenin-noggin-treated MSCs in a
MI animal model. Approximately 80% of the donor MSCs were
positively stained by MEF2-specific antibody in cardiogenin-
activated MSCs that had been transplanted (Fig. 6e). By contrast,
,30% of the donor MSCs treated with noggin were MEF2-
positive (Fig. 6f), signifying that BMP suppression could reduce
cardiomyogenic differentiation of the MSCs in vivo. Western blot
analysis also showed results consistent with immunohistochemical
results in that MEF2 expression in MI hearts transplanted with
cardiogenin-activated MSCs was ,2.6 folds more than that in
those transplanted with cardiogenin-noggin-treated MSCs
(Fig. 6h). Collectively, these results corroborate that inhibition of
BMP-4 leads to reduced CDE of MSCs both in vitro and in vivo,
which is perhaps due to the fact that activation of BMP signaling is
one of the earliest events in CD, as demonstrated by the activation
of signaling pathways, on which full activation of other pathways
and CD may depend.
Discussion
As a whole, this study has demonstrated that the therapeutic
effect to repair infarcted hearts by EGJ or cardiogenin lies
critically in their ability to enhance CDE of endogenous BM-
derived MSCs, which otherwise would occur at a rate too low to
be sufficient for myocardial regeneration. The regenerating
cardiomyocytes observed in this study mainly originated from
BM- derived MSCs. BM-derived haematopoietic stem cells may
be excluded from being a possible contributor in myocardial
regeneration, since a previous study of ours showed that
haematopoietic stem cells could not be induced to undergo CD
by EGJ/cardiogenin (unpublished data). The inability of haema-
topoietic stem cells to differentiate into myocardiocytes is
consistent with other studies [14,15].
It should be noted that recent studies have reported cardiomy-
ocytes derived from transplanted human embryonic stem cells
(hES). Although the findings are of great interest [16,17], the use
of hES may be limited by the potential formation of teratomas
containing derivatives of all three germ layers and immune
rejection [18–21]. Our present results have provided an alternative
way to promote significant myocardial regeneration by a plant
extract or its active compound. The activation of endogenous
MSCs for repair of infarcted heart will eliminate possible teratoma
formation and immune rejection that may be associated with the
use of hES. More importantly, the application of EGJ/cardiogenin
is convenient and safe compared to other treatment strategies
which usually involve cell transplantation or gene manipulation
that may potentially bring about many severe complications.
Therefore, EGJ/cardiogenin should be considered for immediate
development as a new treatment remedy for MI.
The present findings suggest that EGJ/cardiogenin essentially
activates four major signaling pathways to a level sufficient for
myocardial regeneration and repair of infarcted hearts. These
signaling pathways appear to act coherently in a time-dependent
manner to bring about CD, since inhibition of one of the earliest
upregulated molecules, BMP-4, is able to reduce MI repair in vivo
or CD of MSCs in vitro. Interestingly, BMPs has also been shown
to stimulate CD from hES [22]. Together with the present
findings, it implies that BMP-4 may be essential in CD regardless
the cell types, hES or MSCs, from which cardiomyocytes are
derived.
Evidence from this study also suggests possible involvement of
other mechanisms elicited by EGJ/cardiogenin in repair of
infarcted heart. The observed activation/upregulation of Akt1
[23], Bcl2 and cell survival associated pathways, such as JAK-
STAT [24] and NFkB [25–28] pathways in both cardiogenin-
activated MSCs and EGJ-treated MI hearts propose that EGJ/
cardiogenin does have the ability to increase the survival potential
of myocytes at risk along infarct rim and MSCs that migrate to the
infarct zone. The observed numerous DiI-positive regenerating
cardiomyocytes throughout the whole infarct zone of MI hearts
transplanted with EGJ/cardiogenin-activated MSCs, as compared
with a few scattered DiI-positive cells in sham MI hearts, could
also be due to, at least partly, the increased survival potential of
donor cells in the infarct zone.
In addition, many new vessels were observed in the whole
infarct zone within 24 h in the treated, especially EGJ-treated, but
not sham-treated MI hearts. Angiogenesis is required for the
survival, trafficking and growth of cells necessary for the repair of
infarcted heart, indicative of possible angiogenic action of
cardiogenin as well as other possible angiogenic compound(s)
contained in EGJ. The pathways of JAK-STAT and NFkB have
Figure 5. Activation of selective signaling pathways in EGJ-treated MI hearts or cardiogenin-treated MSCs. a, Signaling pathways
including Wnt, TGF-b, JAK-STAT, and NFkB were found similarly activated/up-regulated in both cardiogenin-treated MSCs (E) and EGJ-treated MI
hearts (&) on day 3 after treatment, indicating similar mechanism involved in both cardiogenin-enhanced CDE in MSCs and EGJ-induced myocardial
regeneration. Some CD and cardiac tissue-specific markers were also detected. b, Representative pathway-specific DNA arrays obtained from MSCs
before (i) and 3 days (ii) after cardiogenin treatment (10 mg/ml) with red arrowheads highlighting activation/upregulation of Wnt (4, FGF4), TGF-b (1,
BMP-2; 2, BMP-4), JAK-STAT (5, IL4R; 6, IRF1) and NFkB (3, Ccl20; 7, NFkB1) pathways. The pathway-specific genes were expressed in a time-dependent
manner, monitored over 12 h, 3, 7 and 14 days after cardiogenin treatment (iii). Representative RT-PCR (iv,v) confirmed time-dependent changes in
expression levels of pathway-specific and CD-specific genes in MSCs induced by cardiogenin.
doi:10.1371/journal.pone.0004461.g005
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PLoS ONE | www.plosone.org 11 February 2009 | Volume 4 | Issue 2 | e4461Figure 6. Suppressed CDE in MSCs by BMP-4 inhibition in vitro reduced cardiomyogenesis in vivo. Representative MEF2 immunostaining
micrographs of sham-treated (a), cardiogenin-treated (b) and cardiogenin-noggin-treated (c) MSCs, showed different levels of MEF2 expression.
There were only MEF2-negative cells in the sham-treated (circled in yellow). In sharp contrast, .90% of MEF2-positive cells (brown nuclei) with a few
coexisting negatively stained nuclei were observed after 3 days culture with cardiogenin (10 mg/ml), and ,50% of the MSCs treated with cardiogenin
and noggin (10 ng/ml) were MEF2-negative (c). Representative MEF2-immunostained and DiI-labeled heart tissues demonstrating in vivo CD of
cadiogenin-activated MSCs 7 days after transplantation were also observed. Note that many DiI (orange) and MEF2 (red) colocalized cells (circled in
blue) and many coronary capillaries (circled in yellow) appeared throughout the whole infarct zone (e). Only a few DiI- and MEF2-positive cells were
observed in the infarcted region of the MI hearts transplanted with sham-pretreated MSCs (d). In regard to cardiogenin-noggin-transplanted MSCs,
although many DiI-positive cells were observed in the infarct zone, significantly less MEF2-positive cells were present. Western blots (g, h) were also
performed from cell (a–c for g) and tissue (d–f for h) samples to verify the results in a–f. Bands were produced from M, molecular weight marker; S,
sham-treated; I, noggin-inhibited; and A, cardiogenin-activated MSCs. MEF2 expression in the presence of noggin was ,2.3 folds less than that in
cardiogenin-activated MSCs in vitro. This quantification matches the observations in a–c. Western blot analysis (h)a l s om a t c h e d
immunohistochemistry results in vivo in which MEF2 expression in the presence of noggin (f) was ,2.6 folds less than that in the absence of
noggin (e).
doi:10.1371/journal.pone.0004461.g006
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PLoS ONE | www.plosone.org 12 February 2009 | Volume 4 | Issue 2 | e4461been well documented to induce various angiogenic factors besides
antiapoptotic proteins [24–26]. Thus, activation of these pathways
in cardiogenin-pretreated MSCs may also promote angiogenesis,
and therefore, promote the reconstitution of damaged coronary
vessels and further prevent cell death of transplanted MSCs for
efficient MI repair.
The demonstrated therapeutic effect of EGJ and cardiogenin in
our animal MImodel and enhanced CDE of MSCs in vitro,a sw e l la s
the similar signaling pathways activated by EGJ and cardiogenin
prove that cardiogenin is a major active compound responsible for
significant repair of infarcted hearts. The identification of the
chemical structure and therapeutic effect of cardiogenin, as well as
an underlying mechanism involved, provide ground for immediate
development of new treatment strategies for MI.
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